secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001140361-26-011573
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Rocket's gene therapy KRESLADI for severe LAD-I; Rare Pediatric PRV granted
--------------------------------------------------------------------------------

- KRESLADI (marnetegragene autotemcel) approved for pediatric severe LAD-I with no HLA-matched sibling donor.
- First FDA-approved gene therapy for severe LAD-I; accelerated approval based on CD18/CD11a expression.
- FDA granted Rocket a Rare Pediatric Disease Priority Review Voucher; company plans to evaluate monetization.
- Company to host investor conference call March 27 at 8:30 AM ET.
- Phase 1/2 study principal investigator Donald Kohn, M.D., highlights years of research culminating in approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126011573/0001140361-26-011573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126011573/ef20069038_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-011573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer